CN1276777C - Adenoviral vector SARS vaccine and preparation method thereof, application of coronavirus S gene - Google Patents

Adenoviral vector SARS vaccine and preparation method thereof, application of coronavirus S gene Download PDF

Info

Publication number
CN1276777C
CN1276777C CN 200410044285 CN200410044285A CN1276777C CN 1276777 C CN1276777 C CN 1276777C CN 200410044285 CN200410044285 CN 200410044285 CN 200410044285 A CN200410044285 A CN 200410044285A CN 1276777 C CN1276777 C CN 1276777C
Authority
CN
China
Prior art keywords
sars
gene
adenovirus
preparation
vaccine according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN 200410044285
Other languages
Chinese (zh)
Other versions
CN1562365A (en
Inventor
黄文林
曾益新
汪健
刘然义
黄嘉凌
黄必军
赖坤
吴立志
梁志慧
柯妙拉
吴秀菊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TUMOR PREVENTION AND THERAPY CENTER ZHONGSHAN UNIV
Original Assignee
TUMOR PREVENTION AND THERAPY CENTER ZHONGSHAN UNIV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TUMOR PREVENTION AND THERAPY CENTER ZHONGSHAN UNIV filed Critical TUMOR PREVENTION AND THERAPY CENTER ZHONGSHAN UNIV
Priority to CN 200410044285 priority Critical patent/CN1276777C/en
Publication of CN1562365A publication Critical patent/CN1562365A/en
Application granted granted Critical
Publication of CN1276777C publication Critical patent/CN1276777C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明属于生物基因工程领域,具体涉及腺病毒载体SARS疫苗,其制备方法以及相关冠状病毒S基因在制备预防非典型肺炎(SARS)疫苗方面的应用。通过生物工程手段,将相关冠状病毒S基因与缺陷型腺病毒重组结合,使保护性免疫原蛋白或多肽在其中表达,经过扩增培养、纯化、制剂而制成一种能引起粘膜免疫原性的基因疫苗,诱导呼吸道粘膜免疫反应,使机体产生相应抗体,防止病毒侵染。本发明与传统的灭活病毒颗粒疫苗比较,安全性高,使用方便,不受肌肉注射等特定条件限制,具有广泛的临床应用前景。The invention belongs to the field of biogenetic engineering, and in particular relates to an adenovirus vector SARS vaccine, a preparation method thereof and the application of related coronavirus S gene in preparation of SARS vaccine. By means of bioengineering, the related coronavirus S gene is recombined with the defective adenovirus, so that the protective immunogenic protein or polypeptide is expressed in it, and after amplified culture, purification, and preparation, a drug that can cause mucosal immunogenicity is produced. The genetic vaccine can induce respiratory mucosal immune response, make the body produce corresponding antibodies, and prevent virus infection. Compared with the traditional inactivated virus particle vaccine, the invention has high safety, is convenient to use, is not limited by specific conditions such as intramuscular injection, and has broad clinical application prospects.

Description

Adenovirus Carrier SARS Vaccines And Its Preparation Method, the application of coronavirus S gene
One, technical field
The invention belongs to the biological gene engineering field, be specifically related to adenovirus vector SARS vaccine, its preparation method and the application of announcement associated coronavirus S gene aspect preparation prevention of atypical pneumonia (SARS) vaccine.
Two, background technology
Atypical pneumonia (atypical pneumonia) is broken out in the Chinese Guangdong area since the end of last year, morbidity is anxious, and infectiousness is strong, and antibiotic therapy is invalid.At present, this disease has been transmitted to more than 30 countries and regions, WHO with the respiratory complication of it called after serious acute (severe acuterespiratory syndrome, SARS).
At present, the scientist of world many countries all from different patients serums independent separate to novel coronavirus (coronavirus), the virus gene sequence analysis result shows, they and known coronavirus have 50%~60% homology, The World Health Organization (WHO) announces that the pathogen that causes SARS is the variant of coronavirus.
Coronavirus is a kind of RNA viruses of non-segmental normal chain, and the nearly 30kb of its genome can propagate in humans and animals, the main respiratory system that infects humans and animals, the coronavirus granule is a kind ofly to have inner core and cyst membrane bag by ground virus, has four kinds of structural protein: and spike protein (spike, S), memebrane protein (membrance, M), and envelope protein (envelop, E), and nucleoprotein (nucleoprotein, N).Because coronavirus is a kind of RNA viruses, and is very unstable, undergo mutation easily to escape host's immunological surveillance and repulsion.Therefore, must search out good stability in the SARS associated coronavirus and have the antigen of immanoprotection action, with the development of the vaccine of being correlated with.
The virus particle vaccine of present less application deactivation, because whole virus particles has been carried viral full genome, safety concerns is bigger.Though coronavirus previously easily obtains at In vitro culture, this time the coronavirus toxicity that SARS is relevant greatly and genetic background imperfectly understand, so mass preparation coronavirus granule is infeasible.The exploitation that develops into subunit vaccine of technique for gene engineering provides a great convenience, and the operability of subunit vaccine and biological safety are good.Have immunogenic virus antigen determinant if can screen, in conjunction with technique for gene engineering, can transform antigenic determinant easily, to strengthen its stability, immunogenicity, biological safety.Obviously, by technique for gene engineering, can prepare effective subunit vaccine easily.
According to studies show that at present; in the known four kinds of structural protein of coronavirus; spike protein (spike S) has the structural protein of inducing protective immunological reaction; part scholar's research structure is verified, and coronavirus spike protein C-terminal is its antigen decision family place; simultaneously; the SARS associated coronavirus causes infection by respiratory tract, and the vaccine that can prevent SARS is not arranged at present yet.
In addition, data shows, adenovirus itself is easy to infect the respiratory mucosa epithelium, more easily induce the respiratory mucosa immunoreation, and adenovirus is made the immunogen of vector expression and is expressed in host cell, processes, folds, modifies, offers, basically kept immunogenic native conformation, the biological activity height.
Described condition provides solid theory for utilizing defective adenoviral as carrier development and production adenovirus SARS vaccine.
Three, summary of the invention
First purpose of the present invention is to provide a kind of adenovirus SARS vaccine that can prevent epidemic disease " atypical pneumonia ", better prevents the generation and the propagation of " atypical pneumonia "; Another object of the present invention is to provide a kind of defective adenoviral that utilizes as carrier, by means such as gene clone, reorganization, prepares the method for adenovirus vector SARS vaccine and discloses the application of SARS associated coronavirus S gene in the preparation vaccine.
The object of the present invention is achieved like this: by the biological engineering means, (coronavirus has four structural genes with SARS associated coronavirus S gene, the S gene is one of them, detailed description sees below) combine with the defective adenoviral reorganization, constitute a kind of gene vaccine that can cause mucosal immunity originality.
Used Spike gene fragment order is:
The S gene order of being announced among the use Gene bank (Gene bank query ID:, as follows according to sequential design PCR primer gbAY278554.2) as masterplate:
V1 GGTCTAGAGT?TGTGGTTTCA?AGTGAT
V2 TTTCTAGACC?ATGGGTTGTG?TCCTTGCT
V3 TTTCTAGACC?ATGGCATATA?GGTTCAATG
V4 TAGGTACCAA?TGCCAGTAGT?GGTG
V5 TTGGTACCTC?CGCCTCGACT?TT
V6 CCGGTACCAT?AAGTTCGTTT?ATGTGT
Wherein V1 and V4 are a pair of, amplification S gene N end fragment; V2 and V5 are a pair of primer, amplification S gene M district fragment; V3 and V6 are a pair of primer, amplification S gene C end fragment (as Fig. 1), and the structure after the amplification is seen Fig. 2.
The preparation of adenovirus SARS vaccine:
At first, collect to close and separate rehabilitation patient's serum, obtain the total RNA of coronavirus, by reverse transcription, step such as check order, select and obtain the S gene by separation and Extraction.Then, the S gene clone is obtained clone body (depositary institution: Chinese typical culture collection center to the pShuttle plasmid; Preservation date: on May 17th, 2003; Preserving number: CCTCC M 203036 E.coliDH5a/pShuttle-SN and CCTCC M 203037 E.coli DH5a/pShuttle-SC), again with itself and adenovirus skeleton plasmid (pAdeno-X TM) connect (wherein pShuttle, pAdeno-X be all available from CLONTECH Laboratory, Inc, USA).Connect the common rotaring redyeing 293 cell in back, after further purification is identified, increase in a large number with 293 cells, collect viral liquid, separation and purification is adenovirus SARS vaccine.It can make the medicament of spray or other form.The major technology route is seen Fig. 4.
The present invention is a kind of recombinant vaccine, promptly be to use the gene vaccine of defective adenoviral as carrier, the adenovirus that its utilization itself is easy to infect the respiratory mucosa epithelium expresses former albumen of protective immunity or polypeptide as carrier therein, induces the respiratory mucosa immunoreation; By the mucosa immunity-inducing reaction, make body produce corresponding antibodies, prevent virus infection.The present invention and traditional inactivated virus particle vaccine relatively, it is safe, and easy to use, not limited by specified conditions such as intramuscular injection.
At present, SARS propagates all over the world fast, as a kind of viral infectious, does not find the medicine that can effectively treat now as yet, and in such cases, prevention is best means.Confirmed that now SARS associated coronavirus spike protein C-terminal is its antigen decision family place.Therefore, the present invention is just according to this discovery, synthetic SARS associated coronavirus spike protein gene, it is cloned into adenovirus vector, form through amplification cultivation, purification, preparation, can effectively induce mucosa to produce antibody, produce humoral immunization and prevent the virus infection body, have potential applicability in clinical practice widely.
Four, description of drawings
Fig. 1 is a S gene fragment amplification sketch map.
Fig. 2 is the recombination deficient mutant adenovirus structure chart that has S gene (Spike-S).
Fig. 3 is pShuttle-Sc, pShuttle-S M, pShuttle-S NRecombinant enzyme action result.
Fig. 4 is pShuttle-Sc, pShuttle-S M, pShuttle-S NThe recombinant sequencing result.
Fig. 5 is that RT-PCR detects Ad-S NAnd Ad-S MThe expression result of the test
Fig. 6 is that Western blot detects Ad-S NThe expression result of the test
Fig. 7 is Ad-S NInjection or respiratory immunity all induce female rats to produce the expression in vivo result of the test of specific antibody (IgG)
Fig. 8 is Ad-S NInjection or respiratory immunity all induce male rat to produce the expression in vivo result of the test of specific antibody (IgG)
Fig. 9 is the technology path figure of vaccine production of the present invention.
Five, the specific embodiment
Below will further specify the present invention by specific embodiment.
Embodiment 1
The preparation method of adenovirus vector SARS vaccine:
Two parts that the preparation of adenovirus vector SARS vaccine is divided into that make up early stage and the later stage increases:
Make up early stage:
Obtain SARS associated coronavirus spike (S F, S N, S M, S C) behind the gene, increase with PCR method, behind PCR,, use this enzyme enzyme action pShuttle simultaneously with 37 ℃ of enzyme action of Xbal+Kpnl, connect, transformed into escherichia coli DH5a utilizes kanamycin (Kan R) the resistance screening positive colony, obtain pS behind cultivation, the purification F/ S N/ S M/ S C-Shuttle uses the l-Ceul+Pl-Scel enzyme action, uses this enzyme enzyme action PAdeno-X simultaneously TM, connecting behind the enzyme action, transformed into escherichia coli DH5a utilizes ammonia benzyl (Amp +) the resistance screening positive colony promptly gets pAd-S F/ S N/ S M/ S C
Amplification culture:
Obtain pAd-S F/ S N/ S M/ S CAfter, again through Pacl enzyme action, plasmid transfection incasing cells after linearize, incasing cells is for having integrated the cell line (strain) of C subclass 5 type adenovirus (Ad5) E1 district genes, for example 293 cells.Through plaque select, PCR is accredited as Ad-S F/ S N/ S M/ S CAfter, cultivate 293 cells in a large number, use Ad-S F/ S N/ S M/ S CInfect 293 cells, through the cesium chloride separation and purification, steps such as preparation promptly obtain adenovirus SARS vaccine.
The SARS vaccine comprises SARS associated coronavirus S gene and and defective adenoviral.Defective adenoviral is 5 type adenovirus, i.e. Ad5 of the C subclass that lacks fully of E1 district.The E3 district of this defective adenoviral can or not lack for disappearance or excalation fully.Dress CMV promoter and BGHpolyA in the defective adenoviral.
Ad-S F/S N/S M/S C
Be cloned in the adenovirus vector for SARS associated coronavirus S full length gene.
Be cloned into and comprise S for SARS associated coronavirus S gene in the adenovirus vector 1Domain is in interior sequence.
Be cloned into and comprise S for SARS associated coronavirus S gene in the adenovirus vector 2Domain is in interior sequence.
Be cloned into and comprise S for SARS associated coronavirus S gene in the adenovirus vector 1, S 2(base number is domain: 49~3585) in interior sequence.
Be cloned in the adenovirus vector 3686~3648) and the C end fragment (base number is: for SARS associated coronavirus S gene is striden the film district.
Embodiment 2
Be cloned in the adenovirus vector for SARS associated coronavirus S gene N end fragment.All the other are with embodiment 1.
Embodiment 3
Be cloned in the adenovirus vector for SARS associated coronavirus S gene intermediate segment.All the other are with embodiment 1.
Embodiment 4
Be cloned in the adenovirus vector for SARS associated coronavirus S gene C end fragment.
All the other are with embodiment 1.
Embodiment 5
S gene transformation pShuttle plasmid and evaluation:
With 37 ℃ of water bath condition enzyme action of Xbal+Kpnl, use this enzyme enzyme action pShuttle simultaneously, connect, transformed into escherichia coli DH5a cultivates, and utilizes kanamycin (Kan R) the resistance screening positive colony, obtain pShuttle-Sc, pShuttle-S respectively M, pShuttle-S N, identify and detect Sequence Identification by conventional agargel electrophoresis, the results are shown in Figure 3, Fig. 4.
Embodiment 6
The Ad-S that the clone is obtained N/ S MCarry out the vivoexpression test.
Infect the VeroE6 cell with 2.5~40MOI, discard viral suspension, add cell culture fluid, cultivate under 37 ℃, 5%CO2 condition, collect the cultured cell supernatant in infecting back 48h, detect the expression of Ad-Sn and Ad-Snm respectively with the RT-PCR method, detect the expression of Ad-Sn, the results are shown in Figure 5, Fig. 6 with Western blot method.
Embodiment 7
The Ad-S that the clone is obtained NCarry out the expression in vivo test.
Subjects is divided into groups in the following manner: Ad-Sn collunarium the group, (contrast of Ad-lacZ collunarium group, annotate anesthesia with 3% pentobarbital abdomen earlier, collunarium 0.5mL/ is only), Ad-Sn tail vein injection group, Ad-lacZ tail vein injection group (contrast, tail vein injection administration 0.5mL/ only), blank group (not doing any processing).Administration in the following manner then: be administered once continuous three weeks weekly; After the administration first time, a week get blood, last 2 week of administration the back put to death animals and get blood and tissue, measure rat anti SARS IgG concentration with the ELISA method, the results are shown in Figure 7, Fig. 8.
Embodiment 8
Green monkey kidney cell (Vero E6) cell is avoided SARS and is attacked
1. inoculation Vero E6 cell is to 96 orifice plates, 2 * 10 4/ hole.
2. after 24 hours, inoculate adenovirus SARS vaccine, method: press 4 times of virus dilution stock solutions with RPMI-1640, earlier culture fluid sucking-off in 96 orifice plates is discarded during inoculation, behind the PBS clean-out opening one time, add different dilution viral liquid, each dilution factor adds 5 holes, 50 μ L/ holes.Simultaneously with the negative contrast of RPMI-1640 (not containing virus).37 ℃, 5%CO 2, hatch 1 hour under the saturated humidity condition after, add the RPMI-1640 contain 5% new-born calf serum, 200 μ L/ holes, 37 ℃, 5%CO 2, cultivate under the saturated humidity condition.
3. after 24 hours, inoculate SARS virus, method: RPMI-1640 dilution SARS virus is to 100TCID50, earlier culture fluid sucking-off in 96 orifice plates is discarded during inoculation, behind the PBS clean-out opening one time, add different dilution viral liquid, each dilution factor adds 5 holes, 50 μ L/ holes.Simultaneously with the negative contrast of RPMI-1640 (not containing virus).37 ℃, 5%CO 2, hatch 1 hour under the saturated humidity condition after, add the RPMI-1640 contain 5% new-born calf serum, 200 μ L/ holes, 37 ℃, 5%CO 2, cultivate under the saturated humidity condition.
4. after this observed every 12 to 24 hours and record cytopathy situation, each dilution every porocyte pathological changes scoring addition draws the cytopathy index during result of calculation, gets each class mean, and is as follows:
<110〉Zhongshan Univ. Cancer Cure Center
<120〉Adenovirus Carrier SARS Vaccines And Its Preparation Method, the application of coronavirus S gene
<160>4
<210>1
<211>3780
<212>DNA
<213〉virus is planted
<220>
<221>CDS
<222>(1)…(3780)
<400>1
atgtttattt?tcttattatt?tcttactctc?actagtggta?gtgaccttga?ccggtgcacc 60
acttttgatg?atgttcaagc?tcctaattac?actcaacata?cttcatctat?gaggggggtt 120
tactatcctg?atgaaatttt?tagatcagac?actctttatt?taactcagga?tttatttctt 180
ccattttatt?ctaatgttac?agggtttcat?actattaatc?atacgtttgg?caaccctgtc 240
atacctttta?aggatggtat?ttattttgct?gccacagaga?aatcaaatgt?tgtccgtggt 300
tgggtttttg?gttctaccat?gaacaacaag?tcacagtcgg?tgattattat?taacaattct 360
actaatgttg?ttatacgagc?atgtaacttt?gaattgtgtg?acaacccttt?ctttgctgtt 420
tctaaaccca?tgggtacaca?gacacatact?atgatattcg?ataatgcatt?taattgcact 480
ttcgagtaca?tatctgatgc?cttttcgctt?gatgtttcag?aaaagtcagg?taattttaaa 540
cacttacgag?agtttgtgtt?taaaaataaa?gatgggtttc?tctatgttta?taagggctat 600
caacctatag?atgtagttcg?tgatctacct?tctggtttta?acactttgaa?acctattttt 660
aagttgcctc?ttggtattaa?cattacaaat?tttagagcca?ttcttacagc?cttttcacct 720
gctcaagaca?tttggggcac?gtcagctgca?gcctattttg?ttggctattt?aaagccaact 780
acatttatgc?tcaagtatga?tgaaaatggt?acaatcacag?atgctgttga?ttgttctcaa 840
aatccacttg?ctgaactcaa?atgctctgtt?aagagctttg?agattgacaa?aggaatttac 900
cagacctcta?atttcagggt?tgttccctca?ggagatgttg?tgagattccc?taatattaca 960
aacttgtgtc?cttttggaga?ggtttttaat?gctactaaat?tcccttctgt?ctatgcatgg 1020
gagagaaaaa?aaatttctaa?ttgtgttgct?gattactctg?tgctctacaa?ctcaacattt 1080
ttttcaacct?ttaagtgcta?tggcgtttct?gccactaagt?tgaatgatct?ttgcttctcc 1140
aatgtctatg?cagattcttt?tgtagtcaag?ggagatgatg?taagacaaat?agcgccagga 1200
caaactggtg?ttattgctga?ttataattat?aaattgccag?atgatttcat?gggttgtgtc 1260
c ttgcttgga?atactaggaa?cattgatgct?acttcaactg?gtaattataa?ttataaatat 1320
aggtatctta?gacatggc aa?gcttaggccc?tttgagagag?acatatctaa?tgtgcctttc 1380
tcccctgatg?gcaaaccttg?caccccacct?gctcttaatt?gttat tggcc?attaaatgat 1440
tatggttttt?a caccactac?tggcattggc?taccaacctt?acagagttgt?agtactttct 1500
tttgaacttt?taaatgcacc?ggccacggtt?tgtggaccaa?aattatccac?tgaccttatt 1560
aagaaccagt?gtgtcaattt?taattttaat?ggactcactg?gtactggtgt?gttaactcct 1620
tcttcaaaga?gatttcaacc?atttcaacaa?tttggccgtg?atgtttctga?tttcactgat 1680
tccgttcgag?atcctaaaac?atctgaaata?ttagacattt?caccttgcgc?ttttgggggt 1740
gtaagtgtaa?ttacacctgg?aacaaatgct?tcatctgaag?ttgctgttct?atatcaagat 1800
gttaactgca?ctgatgtttc?tacagcaatt?catgcagatc?aactcacacc?agcttggcgc 1860
atatattcta?ctggaaacaa?tgtattccag?actcaagcag?gctgtcttat?aggagctgag 1920
cat gtcgaca?cttcttatga?gtgcgacatt?cctattggag?ctggcatttg?tgctagttac 1980
catacagttt?ctttat tacg?tagtactagc?caaaaatcta?ttgtggctta?tactatgtct 2040
ttaggtgctg?atagttcaat?tgcttactct?aataacacca?ttgctatacc?tactaacttt 2100
tcaattagca?ttactacaga?agtaatgcct?gtttctatgg?ctaaaacctc?cgtagattgt 2160
aatatgtaca?tctgcggaga?ttctactgaa?tgtgctaatt?tgcttctcca?atatggtagc 2220
ttttgcacac?aactaaatcg?tgcactctca?ggtattgctg?ctgaacagga?tcgcaaca ca 2280
cgtgaagtgt?tcgctcaagt?caaacaaatg?tacaaaaccc?caactttgaa?atattttggt 2340
ggttttaatt?tttcacaaat?attacctgac?cctctaaagc?caactaagag?gtcttttatt 2400
gaggacttgc?tctttaataa?ggtgacactc?gctgatgctg?gcttc atgaa?gcaatatggc 2460
gaatgcctag?gtgatattaa?tgctag agat?ctcatttgtg?cgcagaagtt?caatggactt 2520
acagtgttgc?cacctctgct?cactgatgat?atgattgctg?cctacactgc?tgctctagtt 2580
agtggtactg?ccactgctgg?atggacattt?ggtgctggcg?ctgctcttca?aatacctttt 2640
gctatgcaaa? tggcatatag?gttcaatggc?attggagtta?cccaaaatgt?tctctatgag 2700
aaccaaaaac?aaatcgccaa?ccaatttaac?aaggcgatta?gtcaaattca?agaatcactt 2760
acaacaacat?caactgcatt?gggcaagctg?caagacgttg?ttaaccagaa?tgctcaagca 2820
ttaaacacac?ttgttaaaca?acttagctct?aattttggtg?caatttcaag?tgtgctaaat 2880
gatatcctt t?cgcgacttga?t aaagtcgag?gcggaggtac?aaattgacag?gttaattaca 2940
ggcagacttc?aaagccttca?aacctatgta?acacaacaac?taatcagggc?tgctgaaatc 3000
agggcttctg?ctaatcttgc?tgctactaaa?atgtctgagt?gtgttcttgg?acaatcaaaa 3060
agagttgact?tttgtggaaa?gggctaccac?cttatgtcct?tcccacaagc?agccccgcat 3120
ggtgttgtct?tcctacatgt?cacgtatgtg?ccatcccagg?agaggaactt?caccacagcg 3180
ccagcaattt?gtcatgaagg?caaagcatac?ttccctcgtg?aaggtgtttt?tgtgtttaat 3240
ggcacttctt?ggtttattac?acagaggaac?ttcttttctc?cacaaataat?tactacagac 3300
aatacatttg?tctcaggaaa?ttgtgatgtc?gttattggca?tcattaacaa?cacagtttat 3360
gatcctctgc?aacctgagct?tgactcattc?aaagaagagc?tggacaagta?cttcaaaaat 3420
catacatcac?cagatgttga?tcttggcgac?atttcaggca?ttaacgcttc?tgtcgtcaac 3480
attcaaaaag?aaattgaccg?cctcaatgag?gtcgctaaaa?atttaaatga?atcactcatt 3540
gaccttcaag?aattgggaaa?atatgagcaa?tatattaaat?ggccttggta?tgtttggctc 3600
ggcttcattg?ctggactaat?tgccatcgtc?atggttacaa?tcttgctttg?ttgcatgact 3660
agttgttgca?gttgcctcaa?gggt gcatgc?tcttgtggtt?cttgctgcaa?gtttgatgag 3720
gatgactctg?agccagttct?caagggtgtc?aaattacatt? acacataaac?gaacttatgg 3780
<210>2
<211>50
<212>DNA
<213〉artificial sequence
<220>
<223〉primer (a pair of) that is used for pcr amplification spike gene N end that designs according to spike gene base sequence
<400>2
ggtctagagt?tgtggtttca?agtgat
taggtaccaa?tgccagtagt?ggtg
<210>3
<211>50
<212>DNA
<213〉artificial sequence
<220>
<223〉primer (a pair of) that is used for pcr amplification spike gene M end that designs according to spike gene base sequence
<400>3
tttctagacc?atgggttgtg?tccttgct
ttggtacctc?cgcctcgact?tt
<210>4
<211>50
<212>DNA
<213〉artificial sequence
<220>
<223〉according to the primer that is used for pcr amplification spike gene M end of spike gene base sequence design (to)
<400>4
tttctagacc?atggcatata?ggttcaatg
ccggtaccat?aagttcgttt?atgtgt

Claims (18)

1、一种SARS疫苗,其特征在于它包含SARS相关冠状病毒S基因和复制缺陷型腺病毒。1. A SARS vaccine, characterized in that it comprises a SARS-associated coronavirus S gene and a replication defective adenovirus. 2、根据权利要求1所述的SARS疫苗,其特征在于缺陷型腺病毒为E1区完全缺失的C亚类的5型腺病毒。2. The SARS vaccine according to claim 1, characterized in that the defective adenovirus is a type 5 adenovirus of subtype C with complete deletion of the E1 region. 3、根据权利要求2所述的SARS疫苗,其特征在于缺陷型腺病毒为E3区完全缺失的C亚类的5型腺病毒。3. The SARS vaccine according to claim 2, characterized in that the defective adenovirus is a type 5 adenovirus of subtype C with complete deletion of the E3 region. 4、根据权利要求2所述的SARS疫苗,其特征在于缺陷型腺病毒为E3区部分缺失的C亚类的5型腺病毒。4. The SARS vaccine according to claim 2, characterized in that the defective adenovirus is a type 5 adenovirus of subtype C with partial deletion of the E3 region. 5、根据权利要求2所述的SARS疫苗,其特征在于缺陷型腺病毒为E3区不缺失的C亚类的5型腺病毒。5. The SARS vaccine according to claim 2, characterized in that the defective adenovirus is a type 5 adenovirus of subtype C without deletion of the E3 region. 6、根据权利要求1或2所述的SARS疫苗,其特征在于缺陷型腺病毒内装CMV启动子和BGHpolyA。6. The SARS vaccine according to claim 1 or 2, characterized in that the defective adenovirus contains CMV promoter and BGHpolyA. 7、根据权利要求1或2所述的SARS疫苗,其特征在于它包含SARS相关冠状病毒S基因全长。7. The SARS vaccine according to claim 1 or 2, characterized in that it comprises the full-length S gene of SARS-associated coronavirus. 8、根据权利要求1或2所述的SARS疫苗,其特征在于克隆到腺病毒载体中的为SARS相关冠状病毒S基因包括S1结构域在内的序列。8. The SARS vaccine according to claim 1 or 2, characterized in that the sequence cloned into the adenovirus vector is the sequence of the SARS-associated coronavirus S gene including the S1 domain. 9、根据权利要求1或2所述的SARS疫苗,其特征在于克隆到腺病毒载体中的为SARS相关冠状病毒S基因包括S2结构域在内的序列。9. The SARS vaccine according to claim 1 or 2, characterized in that the sequence cloned into the adenovirus vector is the sequence of the SARS-associated coronavirus S gene including the S2 domain. 10、根据权利要求1或2所述的SARS疫苗,其特征在于克隆到腺病毒载体中的为SARS相关冠状病毒S基因包括S1、S2结构域在内的序列。10. The SARS vaccine according to claim 1 or 2, characterized in that the sequence cloned into the adenovirus vector is the sequence of the SARS-associated coronavirus S gene including the S1 and S2 domains. 11、根据权利要求1或2所述的SARS疫苗,其特征在于克隆到腺病毒载体中的为碱基号为3686~3648的SARS相关冠状病毒S基因跨膜区及C端片段。11. The SARS vaccine according to claim 1 or 2, characterized in that the SARS-associated coronavirus S gene transmembrane region and C-terminal fragment with base numbers 3686-3648 are cloned into the adenovirus vector. 12、一种SARS疫苗的制备方法,包括12. A preparation method for a SARS vaccine, comprising (1)取得SARS相关冠状病毒的S基因;(1) Obtain the S gene of SARS-related coronavirus; (2)将S基因与缺陷型腺病毒重组结合;(2) Recombining the S gene with the defective adenovirus; (3)转染包装细胞;(3) transfect packaging cells; (4)经扩增、分离、纯化,制成制剂。(4) After amplification, separation and purification, the preparation is made. 13、根据权利要求12所述的SARS疫苗制备方法,其特征在于提取S基因后,将其克隆到pshuttle质粒,再将其与腺病毒骨架质粒连接结合。13. The SARS vaccine preparation method according to claim 12, characterized in that after the S gene is extracted, it is cloned into the pshuttle plasmid, and then combined with the adenovirus backbone plasmid. 14、根据权利要求12所述的SARS疫苗的制备方法,其特征在于根据S基因序列设计PCR引物如下:14. The preparation method of SARS vaccine according to claim 12, characterized in that PCR primers are designed according to the S gene sequence as follows: v1  GGTCTAGAGT TGTGGTTTCA AGTGATv1 GGTCTAGAGT TGTGGTTTCA AGTGAT v2  TTTCTAGACC ATGGGTTGTG TCCTTGCTv2 TTTCTAGACC ATGGGTTGTG TCCTTGCT V3  TTTCTAGACC ATGGCATATA GGTTCAATGV3 TTTCTAGACC ATGGCATATA GGTTCAATG V4  TAGGTACCAA TGCCAGTAGT GGTGV4 TAGGTACCAA TGCCAGTAGT GGTG V5  TTGGTACCTC CGCCTCGACT TTV5 TTGGTACCTC CGCCTCGACT TT V6  CCGGTACCAT AAGTTCGTTT ATGTGTV6 CCGGTACCAT AAGTTCGTTT ATGTGT 15、根据权利要求12所述的SARS疫苗制备方法,其特征在于包装细胞为整合了C亚类5型腺病毒Ad5 E1区基因的细胞系或细胞株。15. The preparation method of SARS vaccine according to claim 12, characterized in that the packaging cell is a cell line or cell strain integrated with the gene of Ad5 E1 region of subtype C adenovirus type 5. 16、根据权利要求15所述的SARS疫苗制备方法,其特征在于包装细胞为293细胞。16. The preparation method of SARS vaccine according to claim 15, characterized in that the packaging cells are 293 cells. 17、根据权利要求12所述的SARS疫苗制备方法,其特征在于所述制剂为喷雾剂或注射剂。17. The preparation method of SARS vaccine according to claim 12, characterized in that the preparation is spray or injection. 18、SARS相关冠状病毒S基因在制备预防SARS的疫苗中的应用。18. The application of the S gene of SARS-associated coronavirus in the preparation of a vaccine for preventing SARS.
CN 200410044285 2003-05-21 2004-05-18 Adenoviral vector SARS vaccine and preparation method thereof, application of coronavirus S gene Expired - Fee Related CN1276777C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200410044285 CN1276777C (en) 2003-05-21 2004-05-18 Adenoviral vector SARS vaccine and preparation method thereof, application of coronavirus S gene

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN03126634.7 2003-05-21
CN03126634 2003-05-21
CN 200410044285 CN1276777C (en) 2003-05-21 2004-05-18 Adenoviral vector SARS vaccine and preparation method thereof, application of coronavirus S gene

Publications (2)

Publication Number Publication Date
CN1562365A CN1562365A (en) 2005-01-12
CN1276777C true CN1276777C (en) 2006-09-27

Family

ID=34523618

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200410044285 Expired - Fee Related CN1276777C (en) 2003-05-21 2004-05-18 Adenoviral vector SARS vaccine and preparation method thereof, application of coronavirus S gene

Country Status (1)

Country Link
CN (1) CN1276777C (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006079290A1 (en) * 2005-01-27 2006-08-03 Institute Of Laboratory Animal Science Of Chinese Academy Of Medical Sciences A recombinant sars-cov vaccine comprising attenuated vaccinia virus carriers
CN100479858C (en) * 2005-01-27 2009-04-22 中国医学科学院实验动物研究所 A recombined smallpox vaccine - SARS vaccine and preparation method thereof
CN101020055B (en) * 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 SARS vaccine based on replicative vaccinia virus vector
EP2529227B1 (en) * 2010-01-27 2015-10-07 Oregon Health & Science University Cytomegalovirus-based immunogenic preparations
CN111317816A (en) * 2020-02-05 2020-06-23 翁炳焕 Preparation method of novel coronavirus pneumonia bivalent vaccine
CN113248577B (en) * 2020-02-12 2022-10-21 北京科兴中维生物技术有限公司 Coronavirus vaccine using adenovirus as carrier and its preparing method
CN111228475A (en) * 2020-02-21 2020-06-05 赛诺(深圳)生物医药研究有限公司 Biological product for preventing novel coronavirus
WO2021000969A2 (en) * 2020-02-23 2021-01-07 广州恩宝生物医药科技有限公司 Nucleic acid sequence expressing sars-cov-2 virus antigen peptide and use thereof
PH12021552291A1 (en) * 2020-03-16 2022-08-22 Guangzhou N Biomed Ltd Ad7-vectored vaccine for preventing sars-cov-2 infection
US12128097B2 (en) 2020-03-16 2024-10-29 Guangzhou N Biomed Ltd. AD35-vectored immunogenic composition for SARS-COV-2 infection
CN112206318B (en) * 2020-03-16 2021-08-03 广州恩宝生物医药科技有限公司 Ad7 vector vaccine for preventing SARS-CoV-2 infection
US20210388065A1 (en) * 2020-04-15 2021-12-16 Active Motif Shanghai Limited Antibodies to sars-coronavirus (covid-19) s1 spike protein
CN113750227A (en) * 2020-06-01 2021-12-07 康希诺生物股份公司 SARS-CoV-2 vaccine
CN112143713A (en) * 2020-09-30 2020-12-29 河南牧业经济学院 Recombinant adenovirus expressing porcine deltacoronavirus S1 gene and preparation method
CN112641937B (en) * 2020-10-15 2023-07-04 广州达博生物制品有限公司 Application of recombinant adenovirus in preparation of medicaments for preventing viruses
CN112618707B (en) * 2020-10-15 2023-07-04 广州达博生物制品有限公司 SARS-CoV-2 coronavirus vaccine and its preparation method
US12098384B2 (en) * 2021-01-21 2024-09-24 Cellid Co., Ltd. Adenoviral vector not including replication competent adenovirus, and use thereof
CN114164220B (en) * 2022-01-13 2022-08-12 广州达博生物制品有限公司 Nucleotide sequence for constructing novel coronavirus vaccine and application thereof
CN114807179B (en) * 2022-06-01 2022-10-21 广州达博生物制品有限公司 Construction and application of novel coronavirus pneumonia vaccine

Also Published As

Publication number Publication date
CN1562365A (en) 2005-01-12

Similar Documents

Publication Publication Date Title
CN1276777C (en) Adenoviral vector SARS vaccine and preparation method thereof, application of coronavirus S gene
CN112618707B (en) SARS-CoV-2 coronavirus vaccine and its preparation method
Feng et al. Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity
CN1073878A (en) With virus antigen expression specificity immunogen
CN1912112A (en) Recombinant infectious non-segmented negative strand rna virus
CN1903363A (en) Mosaic type virus-like particle DNA vaccine
CN113896773B (en) Recombinant FCV antigen and feline calicivirus genetic engineering subunit vaccine
CN103627718B (en) Express the dual anti-former Protein reconstitution plasmid of IBV S1 and N and construction method thereof and application
CN101062941A (en) Recombined hepatitis E hepatitis virus protein, preparation method and usage thereof
CN1657102A (en) Epitope-based SARS-Cov Gene Vaccine and Its Construction
CN1821410A (en) Recombinant adenovirus containing codon-optimized HPV16L1 gene
CN1730101A (en) O type foot-and-mouth disease virus poly-gene duplication defect type adenovirus active carrier vaccine and preparation method
CN1225553C (en) Recombinant pseudo-rabies virus expressing swine parvovirus VP2 gene and vacine and its preparation method
CN1276778C (en) SARS nucleic acid vaccine and preparation method thereof
CN114164220B (en) Nucleotide sequence for constructing novel coronavirus vaccine and application thereof
CN1239512A (en) Replication-competent recombinant sabin type 1 strain of pollovirus
CN1943789A (en) The DNA vaccine of an anti-infection of hepatitis C virus
WO2005117961A1 (en) Sars virus vaccine with adenovirus carrier and preparation method thereof , and use of sars virus s gene for preparation of vaccine
CN1769294A (en) Recombinant Akabane virus nucleocapsid protein, its preparation method and application
CN1858062A (en) Enzyme-linked immunosorbent test detecting reagent kit for non-structure protein of pig and cow foot and mouth disease virus
CN1933852A (en) Improved inactivated FCV vaccines
CN1185254C (en) First hypervariable region antigen of hepatitis C and fusion antigen
CN1273482C (en) Hepatitis C virus tunic protein E2 gene capable of being total length expressed in E. coli, its coding protein and use
WO2013030608A1 (en) Nanoparticle-based veterinary vaccine
CN1310677C (en) Method of preparing rabies live carrier vaccine using gland virus carrier expression rabies virus bigene

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Assignee: Shenzhen City Sibiono Gene Technology Co., Ltd.

Assignor: Tumor Prevention and Therapy Center, Zhongshan Univ

Contract fulfillment period: 2007.4.25 to 2024.5.17 contract change

Contract record no.: 2008440000382

Denomination of invention: SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene

Granted publication date: 20060927

License type: Exclusive license

Record date: 20081117

LIC Patent licence contract for exploitation submitted for record

Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.4.25 TO 2024.5.17; CHANGE OF CONTRACT

Name of requester: SHENZHEN CITY SAIBAINUO GENE TECHNOLOGY CO., LTD.

Effective date: 20081117

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060927

Termination date: 20170518

CF01 Termination of patent right due to non-payment of annual fee